Multiple phase I clinical trials using SHP2 inhibitors RMC-4630 and TNO155 are underway targeting KRas mutant NSCLC and other forms of cancer such as head and neck carcinoma (NCT04000529; NCT04330664; NCT03634982) [282]. Here, PTPN11 is linked to non-small cell lung carcinoma.